Tabelecleucel
Ebvallo (tabelecleucel) is a cell pharmaceutical. Tabelecleucel was first approved as Ebvallo on 2022-12-16. It has been approved in Europe to treat lymphoproliferative disorders.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 1 | 1 | 1 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 1 | 2 | — | — | 1 | 3 | |
| Nasopharyngeal neoplasms | D009303 | 1 | 1 | — | — | 1 | 2 | ||
| Epstein-barr virus infections | D020031 | EFO_0000769 | 1 | 1 | — | — | 1 | 2 | |
| Leiomyosarcoma | D007890 | — | 1 | — | — | 1 | 2 | ||
| Primary immunodeficiency diseases | D000081207 | — | 1 | — | — | 1 | 2 | ||
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | 1 | — | — | — | 1 |
| Hemophagocytic lymphohistiocytosis | D051359 | D76.1 | — | 1 | — | — | — | 1 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Aids-related lymphoma | D016483 | EFO_1001365 | — | — | — | — | 1 | 1 | |
| Viremia | D014766 | B34.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TABELECLEUCEL |
| INN | tabelecleucel |
| Description | Tabelecleucel, sold under the brand name Ebvallo, is a medication used for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Tabelecleucel is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in a human leukocyte antigen (HLA)-restricted manner. It is made of cells of the immune system called T-cells that have been taken from the recipient (allogeneic) and are then mixed with EBV-infected B-cells from the same donor.
|
| Classification | Cell |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3990008 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB17072 |
| UNII ID | G3NJ7M8N4H (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 41 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more